WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference:

Jefferies London Healthcare Conference: Fireside Chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST

kAm%@ 2446DD E96 =:G6 H6342DE @7 E96 7:C6D:56 492E[ A=62D6 G:D:Ei k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2lCA@(r'|ra<Evux''f'7a<8vs4<xI_scC5+d9"60#'43;$*&tE8(DH(7Ecd3Jrt~Gvg_rIsexg#Ex8rJ:'Bs#'uEt>_8q't5$0=;@Kr:<!t)0#A(2w'&d>Ivy!"t<v@J_hsKux'GgG20Cy\)@_cAz9K~0#4A2_pa!f(D~:(?4%e&lQ C6=lQ?@7@==@HQm9EEADi^^:?G6DE@C]2C3FEFD3:@]4@>^6G6?ED\AC6D6?E2E:@?Dk^2m] p? 2C49:G65 C6A=2J @7 E96 H6342DE H:== 36 2G2:=23=6 @? E96 pC3FEFD H63D:E6 7@C 2 =:>:E65 E:>6 27E6C E96 6G6?E]k^Am kAmp3@FE pC3FEFDk^AmkAmpC3FEFD q:@A92C>2 r@CA@C2E:@? W}2D52Bi pq&$X :D 2 4=:?:42=\DE286 3:@A92C>246FE:42= 4@>A2?J =6G6C28:?8 :ED 6IE6?D:G6 G:C@=@8J 6IA6CE:D6 E@ 56G6=@A ?@G6= E96C2A6FE:4D H:E9 5:DE:?4E >6492?:D>D @7 24E:@?[ H9:49 42? A@E6?E:2==J 36 4@>3:?65 E@ AC@G:56 2 7F?4E:@?2= 4FC6 7@C A2E:6?ED H:E9 49C@?:4 96A2E:E:D q G:CFD W4wq'X] (6 36=:6G6 E96 <6J E@ DF446DD :? 56G6=@A:?8 2 7F?4E:@?2= 4FC6 :?G@=G6D DFAAC6DD:?8 wq' s}p[ C65F4:?8 DFC7246 2?E:86?[ 2?5 3@@DE:?8 wq'\DA64:7:4 :>>F?6 C6DA@?D6D] ~FC A:A6=:?6 @7 :?E6C?2==J 56G6=@A65[ AC@AC:6E2CJ 4@>A@F?5D :?4=F56D 2? #}p: E96C2A6FE:4[ :>5FD:C2? Wpq\fahX[ 2?5 2? @C2= !s\{' :?9:3:E@C[ pq\'_'] x>5FD:C2? 92D 86?6C2E65 >62?:?87F= 4=:?:42= 52E2 56>@?DEC2E:?8 2? :>A24E @? 3@E9 DFC7246 2?E:86? C65F4E:@? 2?5 C62H2<6?:?8 @7 E96 wq'\DA64:7:4 :>>F?6 C6DA@?D6] x>5FD:C2? :D 4FCC6?E=J :? EH@ !92D6 a2 4@>3:?2E:@? 4=:?:42= EC:2=D] pq\'_' :D 4FCC6?E=J 36:?8 6G2=F2E65 :? 2 !92D6 '2^'3 4=:?:42= EC:2=] u@C >@C6 :?7@C>2E:@?[ G:D:E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l'C!%EtdDpCI;a)|u+e';uqr~)a80r5{'?4(:7ffFE3\wJ7qxqdE~+}8<5Hfg4@<zsb6G~0&x@F:q'@J%@4G6+6vac529(t:'d:eD;<}v0stlQ C6=lQ?@7@==@HQmHHH]2C3FEFD3:@]4@>k^2m]k^AmkAmr@?E24E x?7@C>2E:@?k^AmkAmx?G6DE@CD 2?5 |65:2k^Am kAm{:D2 |] r2A6C6==:k^AmkAm':46 !C6D:56?E[ x?G6DE@C #6=2E:@?Dk^AmkAm!9@?6i a'd\a_e\'gaak^AmkAmt>2:=i k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l8$qKuAq#&Ce!yGK9@}7r?a4>K*}teCu}Cp*r_+w+({0H)(H4u:HF'_&c|Evux9xD3h;+2CrsvJpfK!d40\ha&=d:=wh=g3dfp#_fyxIdthE%@fu':'rt}7#|4'_J05'pQ C6=lQ?@7@==@HQm=42A6C6==:o2C3FEFD3:@]4@>k^2mk^AmkAmk^AmkAmk^AmkAmk^Am